AUS
NZ
UK
CA
USA
IND
Highlights
- PTX-100 granted Fast Track status by US FDA
- Clinical-stage progress enhances commercial pathway
- Phase 2 trial in CTCL advancing toward patient enrolment
Prescient Therapeutics (ASX:PTX) has taken a significant step forward in its oncology development strategy, with the United States Food and Drug Administration (FDA) granting Fast Track Designation to its lead asset, PTX-100. This designation is aimed at expediting the development and review process of PTX-100 for treating adults with relapsed or refractory (r/r) mycosis fungoides, a common form of Cutaneous T Cell Lymphoma (CTCL).
The Fast Track status is designed to support faster access to therapies addressing serious or life-threatening conditions. It allows for rolling submissions of New Drug Applications (NDAs) and increases opportunities for close interaction with the FDA throughout the clinical development process. This development could lead to potential Accelerated Approval, marking a pivotal milestone in Prescient’s commercialisation strategy for PTX-100.
Prescient Therapeutics (ASX:PTX), a clinical-stage oncology company, is focused on advancing innovative therapies for cancers with high unmet medical need. The Fast Track designation underlines the FDA’s recognition of the therapeutic potential PTX-100 has shown in early-stage studies, especially for patients who have limited treatment options.
PTX-100 is a novel first-in-class agent that inhibits geranylgeranyl transferase-1 (GGT-1), a key enzyme in cancer cell survival. By disrupting the activation of specific Ras-related pathways (Rho, Rac, and Ral), PTX-100 induces apoptosis—or programmed cell death—in malignant cells. Currently, it is the only GGT-1 inhibitor believed to be in clinical development globally.
The candidate has shown early signs of safety and efficacy in previous clinical investigations, including a Phase 1 trial and a pharmacokinetics/pharmacodynamics (PK/PD) basket study across both solid and blood cancers. Most recently, it completed a Phase 1b expansion cohort targeting T cell lymphomas, where encouraging results supported further development.
A Phase 2 trial focused on CTCL is now in progress, with site activation completed and patient enrolment expected shortly. Additionally, the FDA has already granted PTX-100 Orphan Drug Designation for all T cell lymphomas, further validating its potential role in rare cancer treatment.
Prescient continues to make strides in advancing PTX-100, aligning its clinical progress with regulatory pathways that may accelerate patient access to this promising therapy.
